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Abstract 
Objectives 
This Liverpool Healthy Lung Programme is a response to high rates of lung cancer and respiratory 
diseases locally and aims to diagnose lung cancer at an earlier stage by proactive approach to 
those at high risk of lung cancer. The objective of this study is to evaluate the programme in terms 
of its likely effect on mortality from lung cancer and its delivery to deprived populations. 
Methods 
Persons aged 58-75 years, with a history of smoking or a diagnosis of chronic obstructive 
pulmonary disease (COPD)1 according to general practice records were invited for lung health 
check in a community health hub setting. A detailed risk assessment and spirometry were 
performed in eligible patients. Those with a 5% or greater five-year risk of lung cancer were 
referred for a low dose CT2 scan.  
Results 
 A total of 4 566 subjects attended the appointment for risk assessment and 3 591 (79%) 
consented to data sharing. More than 80% of the patients were in the most deprived quintile of the 
index of multiple deprivation. Of those attending, 63% underwent spirometry and 43% were 
recommended for a CT scan. A total of 25 cancers were diagnosed, of which 16 (64%) were stage 
I. Comparison with the national stage distribution implied that the programme was reducing lung 
cancer mortality by 22%. 
Conclusions 
                                                             
1 COPD, chronic obstructive pulmonary disease;  
2 CT, computed tomography 
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Community based proactive approaches to early diagnosis of lung cancer in health deprived 
regions are likely to be effective in early detection of lung cancer. 
Key words 
Lung Cancer, Chronic Obstructive Pulmonary Disease, Smoking, Low-Dose CT, Early 
Diagnosis, Health Inequalities 
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Evaluation of a health service adopting proactive approach to reduce high risk of 
lung cancer: the Liverpool Healthy Lung Programme. 
Background 
Lung cancer remains the leading cause of cancer mortality in both males and females in the United 
Kingdom (UK) with around 35 600 deaths in 2016[1]. Lung cancer survival has shown little 
improvement in the last 40 years in the UK[2] and survival rates are lower than elsewhere in 
Europe[3,4]. This is thought to be largely due to late stage diagnosis in the UK compared with 
other European countries[5].  
Several studies have shown that smaller sized and earlier stage lung cancers can be detected 
more accurately by low dose computed tomography (CT) than by symptoms or chest X-ray[6–9]. 
The National Lung Screening Trial (NLST) in the United States (US) showed a 20% reduction in 
lung cancer mortality with early detection using low dose CT as compared to annual chest X-
ray[9]. 
The vast majority of lung cancers (80-90%) can be attributed to cigarette smoking[10], with lesser 
effects of other factors including environmental exposures and genetic susceptibility[11,12]. 
Socio-economic inequalities have been shown to have a significant impact on survival rates for 
the large majority of cancers[13], with poorer outcomes in more deprived populations, suggesting 
that progress in early diagnosis and treatment may have occurred more in affluent 
populations[14,15]. Many studies have reported worse lung cancer survival rates in patients of 
lower socio-economic status[16–18]. Recent data have shown that lung cancer has the largest 
number of excess cases and deaths compared with other cancers in the most deprived quintile of 
the population based on the index of multiple deprivation (IMD)[19].  
In the UK, the city of Liverpool has one of the highest respiratory morbidity rates[20]. The Liverpool 
Healthy Lung Programme (LHLP) is an initiative taken by the Liverpool Clinical Commissioning 
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Group (CCG) to respond to the high rates of respiratory diseases and health inequalities with 
respect to these.  
The programme had two sequential phases. The first was a series of coordinated focused public 
engagement events throughout the city, starting in areas with the highest lung cancer incidence. 
The main aim was to promote positive messages around lung health as well as address attitudes 
of fear and fatalism around lung cancer.  
The second phase, reported on here, was a programme of individual lung health consultations, 
risk assessments and referrals to CT scans for those at more than 5% risk of lung cancer in the 
next five years. It aimed to diagnose respiratory diseases at a more treatable stage thereby 
increase survival rates. 
Material and methods 
Patients aged 58-75 years with a history of smoking or a diagnosis of chronic obstructive 
pulmonary disease (COPD) according to participating general practice records were invited for a 
lung health check (LHC) with a respiratory nurse in a community health hub setting. The first 
invitation letter was followed by a second one in case of non-attendance, and if there was no 
response to the second letter either, the patient was contacted by telephone. 
During the LHC, a detailed risk assessment was performed using information from the subject’s 
medical history and other risk factor information, including exposure to asbestos, family history of 
lung cancer, history of malignancy and smoking duration. Spirometry was used to assess lung 
function in those without a pre-existing diagnosis of COPD. Patients with abnormal lung function, 
defined by FEV1/FVC ratio less than 70% on spirometry, were referred for further investigation. In 
addition to this, all currently smoking patients were offered smoking related advice and referred to 
the National Health Service (NHS) smoking cessation clinics if they consented to this. 
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Five-year risk of lung cancer was estimated using the ‘MyLungRisk’ calculator, based on the 
Liverpool Lung Project (LLP) risk model[21]. Those with risk of 5% or more were referred to a low-
dose CT scan. The participating patients were requested to provide consent to share their data 
with the evaluation team (i.e. the CCG). 
Among the subjects recommended and attending the CT scan, those with clinical signs of lung 
cancer or nodules of diameter 10 mm or greater were referred to cancer services. Those with non-
calcified nodules of diameter 6.1-9.9 mm were suggested to have a follow-up CT scan at 3 months, 
while those with non-calcified nodules of diameter 5-6 mm were offered a scan at 12 months. No 
further action was taken for calcified benign nodules and non-calcified nodules of diameter less 
than 5 mm. 
Here we report on participation, health status, scanning and diagnostic activity between April 2016 
and January 2018. We also carried out surveys of patients post health check and post CT scan, 
to elicit patient experience, satisfaction and information needs. These will be reported on 
separately. 
We compared demographics, risk factors and clinical attributes of patients between the most 
deprived IMD quintile and the four remaining IMD quintiles using logistic regression. The stage 
distribution of lung cancers diagnosed was compared to the national stage distribution using the 
chi-squared test. We estimated the likely effect on lung cancer mortality by applying national stage-
specific fatality rates to the cancers diagnosed in the LHLP and comparing the expected number 
of deaths to the mortality expected from the national stage distribution. A confidence interval was 
calculated by assuming that the observed cancer stages were multinomially distributed and 
national figures were fixed.  All the statistical analyses were performed using Stata version 13.  
Results 
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A total of 11 526 invitations were sent in the first round and 4 566 (40%) attended the appointment. 
Among the attenders, 3 591 (79%) consented for data sharing, 1 264 (35%) took part after the first 
letter, 1 539 (43%) after the second and 788 (22%) after the telephone call. 
(Table 1) 
We had tabular data on non-consenters and non-responders for the 11 526 invitations 
corresponding to the consultations reported on here, plus a further 1 980 from invitations 
subsequent to those for the 3 591 consenters here. Comparing the patients who responded to the 
invitation to a LHC and consented to individual data sharing with those who did not respond and 
those who attended but did not consent to data sharing (Table 1), the age and sex distributions 
were found to be similar for all the groups, although there was a slightly higher proportion of 
females among the non-consenters. The IMD distributions were also slightly different among the 
groups, with 81% in the most deprived quintile among the consenters and 83% for both non-
responders and non-consenters. Correspondingly, approximately 6% of the responders and less 
than 5% of the non-responders and the non-consenters were in the two least deprived quintiles. 
(Table 2) 
Table 2 summarises the attributes of those attending the appointments. Patients were categorised 
into two groups based on their IMD, most deprived (quintile 1) and less deprived (quintiles 2 and 
above). The median age of the patients in the two groups did not differ substantially but, in bivariate 
analysis, age of the patients was found to be significantly (p <0.001) associated with deprivation, 
with those in the most deprived quintile being slightly younger than the less deprived patients. The 
number of patients who had ever smoked in their lifetime and the duration of smoking of the 
patients were significantly higher (p <0.001) in the most deprived category than the less deprived. 
The presences of previous non-lung malignancy and non-malignant lung disease were similar in 
both groups, except for COPD (p < 0.001), which was higher in the most deprived category. 
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Likewise, the 5-year risk of lung cancer was also slightly but significantly (p = 0.005) greater in the 
most deprived group (4.63% vs. 3.45%). 
In both groups, more than 30% reported exposure to asbestos. Of the 1 244 subjects reporting 
exposure in both groups, 338 (27%) were female. 
Of the patients attending the health checks, 745 agreed to receive smoking cessation advice. 
While we did not have data on whether ever smokers were current or ex-smokers, the post-check 
patient survey suggested that 29% of the reported 2 607 ever smokers were current regular or 
occasional smokers. This would imply that 756 patients were current smokers, and 99% of them 
agreed to receive cessation advice. In addition, 128 (17% of estimated current smokers) agreed 
to be referred to a smoking cessation clinic. It is, however, possible that smoking is under-recorded 
in the database. 
(Table 3) 
Table 3 shows the diagnostic cascade for the patients. A total of 2 255 (63%) underwent 
spirometry and 845 (37% of those tested) with a resulting FEV1/FVC ratio of less than 70% were 
referred for further investigation. There were 1 557 (43% of attenders) patients with 5-year lung 
cancer risk greater than or equal to 5% and 1,548 of these (99%) were recommended for a CT 
scan. Of those recommended, 1 318 (85%) had a CT scan at the time data collection was closed. 
Of those undergoing a scan, 119 (9%) were referred for further investigation (follow-up CT scan 
at 3 or 12 months, or immediate referral to pathway) and 25 (1.9%) were diagnosed with lung 
cancer. A further 11 had suspected lung cancer and were undergoing further investigation at the 
time of data download. 
(Table 4) 
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Table 4 shows the expected stage distribution for 25 lung cancers in the general population in the 
UK, and their expected 5-year fatality based on national stage specific survival[22]. This was used 
to calculate the number of predicted deaths in the population by stage. 
The table also shows the staging for the 25 cancers detected within the LHLP. Among these, 16 
(64%) were stage I, 3 (12%) were stage II, 6 (24%) were stage III and none were stage IV. Stage 
I and II cancers comprised 76% of the lung cancers diagnosed, significantly greater than the 22% 
expected from the general lung tumour population (p = 0.003). In absolute terms, there were 11 
fewer Stage III and IV cancers than expected. 
Using national rates of 5-year fatality, it was possible to predict the mortality for the LHLP-detected 
cancers. Based on the stage of cancers diagnosed, we expect about 18 deaths from 25 lung 
cancers detected within the LHLP in the five years following diagnosis. If the LHLP-detected 
cancers had the same stage distribution as the national population of lung cancers, we would have 
expected 23 deaths, suggesting that the programme may be decreasing lung cancer mortality risk 
in patients by 22% (95% CI, 16-30%). Within this cohort, this amounts to just under 5 deaths 
prevented in the coming five years. However, the actual number of deaths prevented will be larger 
than this, since there are cancer data pending from those still under investigation. With the current 
information, it can be said that, among those consenting, the programme is expected to have 
prevented 4-5 deaths from lung cancer. This gives an absolute figure of 264-330 CT scans needed 
per death prevented.  
In terms of socioeconomic status, 23 (92%) of the cancers were diagnosed in the most deprived 
IMD quintile.  
Discussion 
This community-based study was conducted in one of the most deprived regions of the UK as part 
of efforts to address health inequalities in the area. Phase 2 of the LHLP has now been running 
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since April 2016 and has conducted 4 566 lung health checks up to 10th January 2018 (40% of the 
invited population). 
In those referred for and attending a CT scan, a relatively high prevalence (1.9%) of cancers was 
observed. Of the cancers, 76% were at stage I or II, and application of national stage-specific 
survival rates suggest that participation in the programme is associated with a 22% decrease in 
risk of death from lung cancer. This is similar to that observed in the US NLST trial[9]. This relative 
risk reduction corresponds to an absolute prevention of one lung cancer death per 264-330 CT 
scans, rather more than observed in the NLST trial, possibly due to the very high-risk level required 
for eligibility for a CT scan in the LHLP. 
It should be noted that the projected reduction in mortality from lung cancer is tentative at this 
stage. The Danish randomised trial of CT screening found a shift to earlier stage [23] in the CT 
arm but no corresponding reduction in lung cancer mortality [24]. The stage shift could be a length 
bias phenomenon or might at least partly represent overdiagnosis. Further follow-up for lung 
cancer diagnosis and death in the whole screened cohort will clarify this issue. 
Studies have found participation in lung cancer screening to be significantly lower among current 
smokers; especially those living in socio-economically deprived areas [25–28].  Psychological 
factors have been implicated in their low uptake, including fatalistic perceptions of the disease, 
low perceived benefit, individual perceived susceptibility, and perceived stigmatisation of a lung 
cancer diagnosis[28–33]. In our study, uptake was slightly lower in groups of lower socio-economic 
background, but more than 80% of both responders and non-consenters were in the most deprived 
IMD quintile, indicating that the programme was successful in reaching this population. Of our 
patients, 43% attended after the second letter and 22% after the telephone call, which indicates 
that subsequent contact for initial non-attenders was productive.  
In common with others, we found that smoking was more prevalent in the most deprived 
population[34,35]. Smoking is a considerable causal factor of lung disease and premature 
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mortality[36,37] mainly from lung cancer and COPD[1,38]. Smoking status was self-reported in 
this research, and the system of data capture and coding for smoking may be incomplete. It is 
likely that the 73% reported as ever smokers is an underestimate. The project, however, found 
that large proportions of patients agreed to receiving smoking cessation advice, and to be referred 
to smoking cessation services. The protocol of the LHLP has now changed so that patients who 
smoke are referred to smoking cessation services on an opt-out basis. More complete and more 
detailed smoking history should be routinely recorded for future evaluation. 
Approximately one quarter (23%) of patients were found to have an existing diagnosis of COPD. 
Following spirometry of those who did not already have  COPD, 845 (24%) patients had abnormal 
lung function, and from previous local clinical experience it is anticipated that 287 (8%) subjects 
will in due course be diagnosed with and treated for COPD, although rather higher conversion 
rates have been reported in the literature[39]. Even though 85% of those offered a CT scan 
underwent the procedure, this figure is likely to increase as the data for those referred after a 
consultation in January had not yet been processed at the time of download. 
We observed a rate of around 9% of nodules requiring further workup. This is a considerably lower 
rate than observed in previous randomised trials[9,40]. It is at least partly due to the fact that, in 
the LHLP, nodules smaller than 5 mm in diameter were not acted on in order to comply with recent 
guidelines[41]. There is a need for further follow-up of all subjects undergoing health checks to 
assess the extent to which the risk eligibility criteria and the diagnostic algorithm might be causing 
cancers to be missed. Both the low rate of further investigations following a CT scan and the 
promising results with respect to stage of disease are consistent with results from a similar project 
in Manchester[42]. 
There are some limitations to this study in terms of the evaluation and the health intervention. First 
of all, the number of detected cancers is small. However, the stage distribution is so markedly 
different from that of the national lung cancer population that a statistically significant improvement 
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was observed. However, further follow-up is indicated, since as noted above length bias may have 
contributed to the very favourable stage distribution. 
In terms of the health intervention itself, our surveys, which will be reported on in detail elsewhere, 
suggested a gap in information given to patients in terms of the purpose of both the health check 
appointments and the CT scans. Revisiting information materials to address the issue and making 
necessary changes for future application are indicated. Lack of awareness of risk factors in female 
patients was also observed, notably with respect to air pollution, personal smoking history and 
history of non-malignant respiratory disease. With respect to the latter two, it would be worthwhile 
to consider strengthening the printed information or oral information given at consultation.  
The threshold in 5-year lung cancer risk used in the LHLP for referring a patient to a CT scan was 
5%. From the receiver operating characteristics of the LLP model, 42% of lung cancers would be 
estimated to arise in this risk group. Relaxing the criterion to 4% would imply capturing 50% of 
lung cancers, and a 3% criterion would be able to detect 58%. Thus, with a 3% or 4% risk criterion, 
the majority of lung cancers could potentially be diagnosed early in the programme. In this 
population, in addition to the 1 557 subjects meeting the 5% criterion, 290 more would meet the 
4% criterion and a further 337 the 3%. Thus, the increase in scanning activity would lead to similar 
proportional increases in cancers potentially detected early. 
This study suggests that community based proactive approaches to early diagnosis of lung cancer 
in health deprived regions are likely to be effective in early detection of lung cancer and possibly 
COPD. In addition, we could also surmise that such community targeted interventions would 
contribute to improve the population’s health, reduce health inequalities and improve lifestyle and 
life expectancy in the areas where they are implemented. Furthermore, the findings also imply that 
it is feasible to achieve similar clinical outcome benefits to those observed in the US trial of low-
dose CT screening for lung cancer, with lesser harm in terms of unnecessary diagnostic activity[9]. 
However, this needs confirmation with extended follow-up, larger numbers of lung cancers 
diagnosed, and the addition of mortality data. Further randomised trial results would also add to 
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the precision of estimation of benefits and harms, in particular mortality results from the large 
European trial, NELSON[43]. A substantial mortality benefit from CT screening has been reported 
in a conference presentation from NELSON[44], and the published results are awaited with great 
interest. 
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* One responder had missing IMD data. 
SD = Standard Deviation 
IMD = Index of Multiple Deprivation 
 
 
  
Table 1. Age, sex and IMD for the responders giving consent to individual data sharing, the non-responders, 
and the responders not giving consent to individual data sharing. 
Factor Category/quantity Responders 
(N = 3,591) 
n (%) 
Non-responders 
(N = 8,898) 
n (%) 
Non-consenters 
(N = 1,017) 
n (%) 
Age Mean (SD) 65.9 (4.3) 65.4 (4.6) 66.2 (4.7) 
Sex Male 1,853 (52) 4,679 (53) 499 (49) 
 Female 1,738 (48) 4,219 (47) 518 (51) 
IMD quintile*  1 (most deprived) 2,897 (81) 7,415 (83) 846 (83) 
 2 275 (8) 725 (8) 69 (7) 
 3 212 (6) 415 (5) 61 (6) 
 4 194 (5) 317 (4) 40 (4) 
 5 (least deprived) 12 (<1) 26 (<1) 1 (<1) 
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* One attender had missing IMD data and is therefore not represented in this table. 
Table 2. Demographics and respiratory characteristics of patients attending healthy lung appointment 
(consented patients only).* 
  Most deprived  
(IMD quintile = 1) 
n (%) 
Less deprived  
(IMD quintile >= 2) 
n (%) 
p value 
Factors Category/quantity    
     
Total patients  2,897 (80.7) 693 (19.3)  
     
     
     
Age Median (p25,p75) 66 (62, 69) 67 (63, 70) <0.001 
     
Sex  Female 1,418 (48.9) 319 (46.0) 0.168 
 Male 1,479 (51.1) 374 (54.0)  
     
Ever smoker Yes 2,141 (73.9) 461 (66.5) <0.001 
 No 756 (26.1) 232 (33.5)  
     
Years smoked Median (p25,p75) 40 (25, 47) 30 (16, 44) <0.001 
     
 FEV1/FVC ratio Median (p25,p75) 0.73 (0.67, 0.77) 0.73 (0.67, 0.77) 0.361 
     
Previous non-lung 
malignancy 
Yes 420 (14.5) 106 (15.3) 0.594 
 No 2,477 (85.5) 587 (84.7)  
     
Non-malignant lung 
disease 
Emphysema 103 (3.6) 16 (2.3) 0.102 
 Pneumonia 511 (17.6) 121 (17.5) 0.912 
 COPD 717 (24.75) 114 (16.45) <0.001 
 Bronchitis 983 (33.9) 223 (32.2) 0.380 
 Tuberculosis 53 (1.8) 11 (1.6) 0.665 
     
Asbestos exposure  Yes 992 (34.2) 252 (36.4) 0.292 
 No 1905 (65.8) 441 (63.6)  
     
Family history of lung 
cancer 
Yes 966 (33.3) 206 (29.7) 0.068 
 No 1,931 (66.7) 487 (70.3)  
     
Lung cancer risk Median (p25, p75) 4.63 (2.16, 8.66) 3.46 (1.66, 7.68) 0.005 
 More than 5% 1,492 (53.5) 414 (61.4)  
 Less than 5% 1,295 (46.5) 260 (38.6)  
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FVC = Forced Vital Capacity, FEV1 = Forced expiratory volume in one second 
 
 
 
 
LHLP = Liverpool Healthy Lung Programme 
CT = Computed Tomography 
 
 
 
 
Table 4. Stage distribution of the UK lung cancer population and of the LHLP-detected lung cancers, with 
expected numbers of deaths in five years predicted from national stage-specific survival rates. 
Stage UK expected 
population 
frequency  
(n, %) 
UK 5-year 
fatality 
(%) 
UK predicted 
deaths 
(n) 
LHLP 
observed 
frequency  
(%) 
LHLP 
predicted 
deaths 
(n) 
Unknown 2 (10) 94 1.9 0 (0) 0 
I 4 (15) 65 2.6 16 (64) 10.4 
II* 2 (7) 79 1.6 3 (12) 2.4 
III 5 (19) 94 4.7 6 (24) 5.6 
IV 12 (49) 100 12 0 (0) 0 
Total 25 (100) 90 22.8 25 (100) 18.4 
*One thymoma is included with the stage II cancers 
UK = United Kingdom 
LHLP = Liverpool Healthy Lung Programme 
 
 
 
 
Table 3. Diagnostic cascade within LHLP (consented patients only). 
Outcome Number Percentage  
Patients attending 3,591  
Spirometry 2,255 63% (of attenders) 
CT scan recommended 1,548 43% (of attenders) 
CT scan carried out 1,318 37%(of attenders), 85% (of recommended) 
Further investigation for nodules 119 9% (of scanned) 
Lung cancer 25 1.9% (of scanned) 
Suspicious lesion under investigation 11 0.8% (of scanned) 
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